ExAblate 2000 offers women the only non-invasive option for treatment of symptomatic uterine fibroids
Haifa, Israel– October 19, 2005 – To ensure that more women have access to and learn about non-invasive treatment options for symptomatic uterine fibroids, InSightec has launched an educational program on its ExAblate® 2000 procedure for obstetrician/gynecologists (OB/GYNs), the company said today. The ExAblate® 2000 will be highlighted at two OB/GYN medical conferences this fall: the meeting of the 61st Annual meeting of the American Society for Reproductive Medicine (ASRM) held conjointly with the Canadian Fertility and Andrology Society, October 15-19 in Montreal; as well as the Global Congress of Minimally Invasive Gynecology at the American Association of Gynecologic Laparoscopists (AAGL) 34th Annual Meeting in Chicago, November 9 -12.
The ExAblate 2000 combines magnetic resonance imaging (MRI) with highly-focused ultrasound to destroy tumors non-invasively in the body. ExAblate 2000 is the first U.S. Food and Drug Administration-approved system to use the breakthrough MR-guided focused ultrasound technology that combines MRI to visualize the uterus and high intensity focused ultrasound to thermally ablate or destroy harmful tissue.
To date, approximately 1,200 women have been treated with ExAblate 2000 for uterine fibroids, a benign condition that affects approximately 25 percent of women. Clinical trials are underway for bone, liver, and breast tumors.
At ASRM on Saturday, Oct. 15, Elizabeth A. Stewart, M.D., Clinical Director of the Center for Uterine Fibroids at Brigham and Women's Hospital and Associate Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School, discussed research on this modality of treatment for uterine fibroids as a part of her presentation of Innovative Therapies in the session entitled "Modern Approaches to Uterine Fibroids."
"As the body of clinical data continues to grow in support of minimally- and non-invasive techniques for uterine fibroids, more OB/GYNs are recognizing the value this new MR-guided focused ultrasound technology holds for treating women with symptomatic uterine fibroids," said Dr. Stewart. "Women who may not have previously undergone uterine fibroid therapy because of the hospital stays, risks and side effects involved with traditional treatments now have the option to threat their condition in the outpatient setting without surgery."
At ASRM, InSightec exhibited the ExAblate 2000 in the GE Healthcare booths (#113 and #117). In August, InSightec signed a global sales and marketing agreement with GE Healthcare for the sales and marketing of its ExAblate® 2000. The ExAblate 2000 works exclusively with the Signa MR systems made by GE Healthcare.
At AAGL, InSightec will exhibit the ExAblate 2000 at booth #718. In addition, the ExAblate 2000 will be discussed during a postgraduate course on excisional and non-excisional management of uterine leiomyomas during the conference on Wednesday, Nov. 9th.
InSightec Image Guided Treatment Ltd. is a privately held company owned by Elbit Medical Imaging (EMI), General Electric, private investors and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 100 employees and has invested more than $80 million in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas. For more information, please go to: http://www.insightec.com/
For media inquiries, contact:
Lazar Partners, Ltd.
Tel: (212) 867-1762
For more information about uterine fibroids, please visit http://www.uterine-fibroids.org